Last updated: February 24, 2026
What is NDC 33342-0138?
NDC 33342-0138 corresponds to Firdapse (amifampridine) tablets, approved by the FDA in 2019 for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). It was originally approved under the FDA's orphan drug status. As a proprietary product of Catalyst Pharmaceuticals, Firdapse has a unique position in the treatment landscape for neuromuscular disorders.
Market Landscape
Therapeutic Area Overview
Firdapse targets LEMS, a rare autoimmune neuromuscular disorder characterized by muscle weakness. The prevalence in the U.S. is approximately 3 per million, with an estimated patient population of around 1,000 patients nationally. The treatment landscape for LEMS is limited, with Firdapse representing the only FDA-approved medication specifically for this condition.
Competitive Environment
- Off-label treatments include 3,4-diaminopyridine (3,4-DAP), compounded formulations, and symptom management therapies.
- No other FDA-approved drugs directly compete for LEMS treatment.
- The proprietary nature and orphan drug status lend pricing and market exclusivity advantages to Firdapse.
Revenue and Sales Trends
- Analysts estimate sales of Firdapse in 2022 at approximately $350 million.
- Catalyst Pharmaceuticals reported approximately $500 million in sales for 2022, reflecting increased demand.
- Sales growth is driven by expanding awareness, higher treatment rates, and renewed drug approvals in certain regions.
Regulatory and Reimbursement Environment
- Orphan drug designation provides 7-year market exclusivity.
- Firdapse's price is high due to small patient population and high treatment value, with typical wholesale acquisition costs (WAC) around $20,000 per month per patient.
- Reimbursement aligns with Medicare and Medicaid policies, with prior authorization often required.
Price Projections
Current Pricing
- Wholesale acquisition cost (WAC): Roughly $20,000–$23,000 per month.
- Annual treatment cost: Approximately $240,000–$276,000 per patient.
- Patient access: Conservative estimates suggest 80–100% treatment adoption among diagnosed patients.
Short to Medium Term (Next 2-3 Years)
- Price stability: Given limited competition and regulatory exclusivity, prices are unlikely to decrease significantly.
- Pricing pressures: May emerge from policy reforms aimed at high-cost rare disease drugs, but unlikely to impact immediate pricing trends.
- Market expansion: Growth driven by increased diagnosis, awareness, and access.
Long Term (3–5 Years)
- Patent and exclusivity: The orphan drug exclusivity may extend until 2026–2028; biosimilar or generic entry is unlikely due to small market size and regulatory hurdles.
- Pricing trend: Prices are expected to stay stable or increase modestly, considering inflation and healthcare cost trends.
- Potential Market Expansion: Broader adoption in off-label indications or new geographic regions may influence revenues slightly but will not affect price per unit significantly.
External Influences
- Regulatory changes: Stricter pricing controls could pressure prices, although rare disease drugs are often shielded.
- Market shifts: Introduction of alternative therapies or biosimilars could impact demand and pricing.
Summary Table
| Factor |
Current Status |
Short-Term Projection |
Long-Term Projection |
| Price (WAC/month) |
~$20,000–$23,000 |
Stable |
Slight increase or stability |
| Revenue (2022) |
~$350 million |
Maintains or modest growth |
Sustained due to limited competition |
| Patent/Exclusivity |
Until ~2026–2028 |
No change unless legal challenges |
Patents likely extended if relevant |
| Competition |
None for approved indication |
No significant competition |
No biosimilar threat anticipated |
Key Takeaways
- NDC 33342-0138 (Firdapse) functions as a near-monopoly product with high pricing due to small patient population.
- Revenue remains robust, driven by consistent demand, with prices stable or slightly increasing.
- Regulatory exclusivities and limited competition sustain pricing power.
- External policy pressures could affect future pricing but are unlikely to cause abrupt decreases.
FAQs
1. Is the price of Firdapse expected to decrease?
Prices are unlikely to decrease significantly in the short term due to market exclusivity and limited competition. Moderate increases driven by inflation are possible.
2. How many patients are estimated to use Firdapse?
Approximately 1,000 patients in the U.S., with access capacities expanding as awareness increases.
3. What factors could influence future pricing?
Regulatory changes, patent challenges, or the introduction of biosimilars could impact pricing, but none are imminent.
4. Are there any significant competitors?
No. Firdapse currently has no direct FDA-approved competitors for LEMS.
5. What is the outlook for brand expansion?
Limited potential exists for expansion beyond current indications. Off-label use may grow but is unlikely to affect supply prices significantly.
References
- Catalyst Pharmaceuticals. (2023). Firdapse Prescribing Information.
- IQVIA. (2022). U.S. Prescription Drug Database.
- U.S. Food and Drug Administration. (2019). Approval memorandum for Firdapse.
- Cotter, A. et al. (2021). "Treatment landscape for Lambert-Eaton Myasthenic Syndrome." Neuromuscular Disorders.
- Evaluate Pharma. (2022). "Rare Disease Market Report."
